My major research efforts currently are: a) defining mechanisms of stromal/epithelial-immune cell cross talk in IBD; b) defining components of treatment refractory (specifically, non-response to pro-inflammatory cytokine blockade) IBD at the cellular and tissue level; c) predicting differences in clinical outcomes of interest across IBD clinical subtypes and populations; d) exploring the role of rare, IBD-associated variants of high effects; e) organizing large datasets for NIDDK IBDGC and IIBDGC; and f) developing select treatment targets based on IBD genetic and single cell expression findings. Since 2015, I have served as Director of the Personalized Medicine Institute at Mount Sinai. I am extremely excited by the explosion of data and new data tools that are accelerating collaborative efforts to benefit patients through genetic and genomic studies; I am eager to continue applying new data-approaches to benefit the NIDDK IBDGC.
Aim 1: To function as a multi-disciplinary genetics research center (GRC) in Consortium-wide projects. To recruit populations prioritized by the NIDDK IBDGC, including non-European cohorts. To ascertain and participate in intestine-focused, cross-Consortium studies. To pilot novel clinical research approaches, to scale select approaches across the NIDDK IBDGC. To deepen longitudinal phenotype data for recruited patients.
Aim 2: To define intestinal single-cell expression features with anti-TNF non-response and response in ileal resection and inception Crohn’s cohorts. To identify key measurements for large cohort, longitudinal analyses.
Aim 1: Optimize cell isolation protocols and surface marker selection for CITE-Seq studies.
Aim 2: To apply optimized CITE-Seq protocols to Crohn’s disease resection tissues: comparing classic lineage to GWAS-prioritized surface protein expression
Aim 3: Improve imputation of single cell-based insights onto larger datasets: developing new expression quantitative traits and defining pathophysiologic heterogeneity
Bruce Sands, MD, MS is the Dr. Burrill B. Crohn Professor of Medicine. Dr. Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. He joined Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Prior to joining Mount Sinai, Dr. Sands was Medical Co-Director of the Crohn’s & Colitis Center at Massachusetts General Hospital in Boston, where he also served as the hospital’s Acting Chief of the Gastrointestinal Unit as well as Associate Professor of Medicine at Harvard Medical School.
Miriam Merad, M.D.; Ph.D. is the Mount Sinai Endowed professor in Cancer Immunology and the Director of the Precision Immunology Institute at Mount Sinai School of Medicine in New York. Dr. Merad also co-leads, the Cancer Immunology program at The Mount Sinai Tisch Cancer Institute and is the Director of the Mount Sinai Human Immune Monitoring Center (HIMC).
Dr. Hao is currently an associate professor of the Department of Genetics and Genomic Sciences and a member of Icahn Institute of Data Science and Genomic Technology. Dr. Hao received his ScD degree and postdoc training at Harvard University and has extensive expertise in statistical genetics, computational biology and environmental health. Over the past decade, Dr. Hao has contributed significantly in these areas. He systematically collected large datasets of human tissue samples, and generated molecular trait quantitative loci (xQTLs), including adipose, blood vessel wall, skeleton muscle, lung, liver, brain, placenta, intestine, whole blood, monocyte, macrophage, etc. Further he integrated the xQTLs with large GWAS data to identify genetic basis of human diseases and discover the mechanism: genetic variants → molecular/cellular alternation → disease.
Dr. Ephraim Kenigsberg is an Assistant Professor for the Department of Genetics and Genomic Sciences and the Icahn Institute for Data Science and Genomic Technology.